Annual report pursuant to Section 13 and 15(d)

Note 1 - Nature of Operations and Summary of Significant Accounting Policies

v3.7.0.1
Note 1 - Nature of Operations and Summary of Significant Accounting Policies
12 Months Ended
Dec. 31, 2016
Notes to Financial Statements  
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]
Note
1:
Nature of Operations and Summary of Significant Accounting Policies
 
Principles of Consolidation
 
The accompanying consolidated financial statements include the accounts of The Joint Corp. and its wholly owned subsidiary, The Joint Corporate Unit No.
1,
LLC (collectively, the “Company”), which was dormant for all periods presented.
 
All significant intercompany accounts and transactions between The Joint Corp. and its subsidiary have been eliminated in consolidation. Certain balances were reclassified from selling and marketing expenses to general and administrative expenses for the year ended
December
31,
2015
to conform to current year presentation.
 
Comprehensive Loss
 
 Net loss and comprehensive loss are the same for the years ended
December
31,
2016
and
2015.
 
Nature of Operations
 
The Joint Corp., a Delaware corporation, was formed on
March
10,
2010.
Its principal business purposes are owning, operating, managing and franchising chiropractic clinics, selling regional developer rights and supporting the operations of owned, managed and franchised chiropractic clinics at locations throughout the United States of America. The franchising of chiropractic clinics is regulated by the Federal Trade Commission and various state authorities.
 
The following table summarizes the number of clinics in operation under franchise agreements and as company-owned or managed for the years ended
December
31,
2016
and
2015:
 
    Year Ended
 December 31,
Franchised clinics:   2016   2015
Clinics in operation at beginning of period    
265
     
242
 
Opened during the period    
56
     
54
 
Acquired during the period    
(6
)    
(24
)
Closed during the period    
(6
)    
(7
)
Clinics in operation at the end of the period    
309
     
265
 
 
    Year Ended
 December 31,
Company-owned or managed clinics:   2016   2015
Clinics in operation at beginning of period    
47
     
4
 
Opened during the period    
8
     
21
 
Acquired during the period    
6
     
24
 
Closed during the period    
-
     
(2
)
Clinics in operation at the end of the period    
61
     
47
 
                 
Total clinics in operation at the end of the period    
370
     
312
 
                 
Clinic licenses sold but not yet developed    
115
     
168
 
 
Management's Plans
 
As of
December
31,
2016,
the Company had cash and short-term bank deposits of approximately
$3.0
million. To preserve cash, the Company does not plan to add any company-owned or managed clinics during the
2017
fiscal year. Additionally, in
December
2016,
the Company made the decision to close or sell
14
clinics in Chicago and New York. As a result, the Company has significantly reduced its estimated cash needs for
2017
to approximately
$2.0
million. The cash used in
2016
included expenditures for the acquisition or development of
14
company-owned or managed clinics, and the working capital losses in the Chicago and New York markets which amounted to approximately
$2.8
million for the year ended
December
31,
2016.
As the Company has no current plans to acquire or develop company-owned or managed clinics during
2017,
and has sold or closed the
14
clinics in the Chicago and New York markets, the Company’s projected use of cash in
2017
is significantly lower than the amount of cash used in
2016.
Furthermore, in
January
2017,
the Company executed a Credit and Security Agreement which provided a credit facility of up to
$5.0
million. Taking into account these tactical decisions made by the Company’s management, as well as the execution of the credit facility, the Company has concluded that it can continue as a going concern for at least
one
year from the date that the financial statements were available to be issued.
 
Variable Interest Entities
 
An entity deemed to hold the controlling interest in a voting interest entity or deemed to be the primary beneficiary of a variable interest entity (“VIE”) is required to consolidate the VIE in its financial statements. An entity is deemed to be the primary beneficiary of a VIE if it has both of the following characteristics: (a) the power to direct the activities of a VIE that most significantly impact the VIE's economic performance and (b) the obligation to absorb the majority of losses of the VIE or the right to receive the majority of benefits from the VIE. Investments where the Company does not hold the controlling interest and are not the primary beneficiary are accounted for under the equity method.
 
Certain states in which the Company manages clinics, regulate the practice of chiropractic care and require that chiropractic services be provided by legal entities organized under state laws as professional corporations or PCs. Such PCs are VIEs. In these states, the Company has entered into management services agreements with PCs under which the Company provides on an exclusive basis, all non-clinical services of the chiropractic practice. The Company has analyzed its relationship with the PCs and has determined that the Company does not have the power to direct the activities of the PCs. As such, the activity of the PCs is not included in the Company’s consolidated financial statements
 
Cash and Cash Equivalents
 
The Company considers all highly liquid instruments purchased with an original maturity of
three
months or less to be cash equivalents. The Company continually monitors its positions with, and credit quality of, the financial institutions with which it invests. As of the balance sheet date and periodically throughout the period, the Company has maintained balances in various operating accounts in excess of federally insured limits. The Company has invested substantially all of the proceeds of its public offerings in short-term bank deposits. The Company had no cash equivalents as of
December
31,
2016
and
2015.
 
Restricted Cash
 
Restricted cash relates to cash franchisees and corporate clinics contribute to the Company’s National Marketing Fund and cash franchisees provide to various voluntary regional Co-Op Marketing Funds. Cash contributed by franchisees to the National Marketing Fund is to be used in accordance with the Franchise Disclosure Document with a focus on regional and national marketing and advertising.
 
Concentrations of Credit Risk
 
From time to time the Company grants credit in the normal course of business to PCs or franchisees related to the working capital needs of the PC, collection of royalties, or other operating revenues. The Company periodically performs credit analysis and monitors the financial condition of the PCs or franchisees to reduce credit risk. As of
December
31,
2016
and
2015,
one
PC entity, and
six
franchisees represented
24%
and
31%,
respectively, of outstanding accounts receivable. The Company did not have any PCs or franchisees that represented greater than
10%
of our revenues during the years ended
December
31,
2016
and
2015.
 
Accounts Receivable
 
Accounts receivable represent amounts due from franchisees for initial franchise fees, royalty fees, marketing and advertising expenses and amounts due from PCs for which we perform management services for the repayment of working capital advances. The Company considers an allowance for doubtful accounts based on the creditworthiness of the franchisee or named entity. The provision for uncollectible amounts is continually reviewed and adjusted to maintain the allowance at a level considered adequate to cover future losses. The allowance is management’s best estimate of uncollectible amounts and is determined based on specific identification and historical performance that the Company tracks on an ongoing basis. The losses ultimately could differ materially in the near term from the amounts estimated in determining the allowance. As of
December
31,
2016
and
2015,
the Company had an allowance for doubtful accounts of
$131,830
and
$142,660,
respectively.
 
The Company writes off accounts receivable when it deems them uncollectible and records recoveries of accounts receivable previously written off when it receives them. In
December,
2016,
the Company determined that certain working capital advances from its PC entities in Illinois and New York were no longer collectible as a result of the sale or closure of the related clinics. Accordingly, the Company wrote-off
$731,857
of accounts receivable to loss on disposition or impairment related to these entities during the year ended
December
31,
2016.
  
Deferred Franchise Costs
 
Deferred franchise costs represent commissions that are paid in conjunction with the sale of a franchise and are expensed when the respective revenue is recognized, which is generally upon the opening of a clinic.
 
Property and Equipment
 
Property and equipment are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of
three
to
seven
years. Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or the estimated useful life of the assets.
 
Maintenance and repairs are charged to expense as incurred; major renewals and improvements are capitalized. When items of property or equipment are sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is included in income.
 
Software Developed
 
The Company capitalizes certain software development costs. These capitalized costs are primarily related to proprietary software used by clinics for operations and by the Company for the management of operations. Costs incurred in the preliminary stages of development are expensed as incurred. Once an application has reached the development stage, internal and external costs, if direct, are capitalized as assets in progress until the software is substantially complete and ready for its intended use. Capitalization ceases upon completion of all substantial testing. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Software developed is recorded as part of property and equipment. Maintenance and training costs are expensed as incurred. Internal use software is amortized on a straight line basis over its estimated useful life, generally
5
years.
 
Intangible Assets
 
Intangible assets consist primarily of re-acquired franchise and regional developer rights and customer relationships.  The Company amortizes the fair value of re-acquired franchise rights over the remaining contractual terms of the re-acquired franchise rights at the time of the acquisition, which range from
six
to
eight
years. The Company amortizes the acquired regional developer rights over
seven
years. The fair value of customer relationships is amortized over their estimated useful life of 
two
 years.
 
The Company recorded an impairment charge of
$38,185
during the year ended
December
31,
2016
related to closure of an acquired clinic in New York.
 
Goodwill
 
Goodwill consists of the excess of the purchase price over the fair value of tangible and identifiable intangible assets acquired in the acquisitions discussed in Note
2.
  Goodwill and intangible assets deemed to have indefinite lives are not amortized but are subject to annual impairment tests. As required, the Company performs an annual impairment test of goodwill as of the
first
day of the
fourth
quarter or more frequently if events or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value.
 
The Company recorded an impairment charge of
$54,994
during the year ended
December
31,
2016
which represents the write-off of the goodwill associated with the closure of an acquired clinic in New York.
 
Long-Lived Assets
 
The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset
may
not be recovered. The Company looks primarily to estimated undiscounted future cash flows in its assessment of whether or not long-lived assets have been impaired. Impairments of approximately
$2.4
million and
$0
were recorded for the years ended
December
31,
2016
and
2015,
respectively.
 
Advertising Fund
 
The Company has established an advertising fund for national/regional marketing and advertising of services offered by its clinics. The monthly marketing fee is
2%
of clinic sales. The Company segregates the marketing funds collected which are included in restricted cash on its consolidated balance sheets. As amounts are expended from the fund, the Company recognizes advertising fund revenue and a related expense. Amounts collected in excess of marketing expenditures are included in restricted cash on the Company’s consolidated balance sheets. 
  
Co-Op Marketing Funds
 
Some franchises have established regional Co-Ops for advertising within their local and regional markets. The Company maintains a custodial relationship under which the marketing funds collected are segregated and used for the purposes specified by the Co-Ops’ officers. The marketing funds are included in restricted cash on the Company’s consolidated balance sheets.
 
Accounting for Costs Associated with Exit or Disposal Activities
 
The Company recognizes a liability for the cost associated with an exit or disposal activity that is measured initially at its fair value in the period in which the liability is incurred.
 
Costs to terminate an operating lease or other contracts are (a) costs to terminate the contract before the end of its term or (b) costs that will continue to be incurred under the contract for its remaining term without economic benefit to the entity. A liability for costs that will continue to be incurred under a contract for its remaining term without economic benefit to the entity shall be recognized at the cease-use date. In periods subsequent to initial measurement, changes to the liability are measured using the credit adjusted risk-free rate that was used to measure the liability initially. The cumulative effect of a change resulting from a revision to either the timing or the amount of estimated cash flows shall be recognized as an adjustment to the liability in the period of the change.
 
As of
December
31,
2016
the Company recognized a liability of approximately
$0.3
million related to operating leases that will no longer provide economic benefit to the entity, net of estimated sublease income.
 
Deferred Rent
 
The Company leases office space for its corporate offices and company-owned and managed clinics under operating leases, which
may
include rent holidays and rent escalation clauses.  It recognizes rent holiday periods and scheduled rent increases on a straight-line basis over the term of the lease.  The Company records
tenant
improvement allowances as deferred rent and amortizes the allowance over the term of the lease, as a reduction to rent expense.
 
Revenue Recognition
 
The Company generates revenue through initial franchise fees, regional developer fees, royalties, advertising fund revenue, IT related income, and computer software fees, and from its company-owned and managed clinics.
 
Franchise Fees.
The Company requires the entire non-refundable initial franchise fee to be paid upon execution of a franchise agreement, which typically has an initial term of
ten
years. Initial franchise fees are recognized as revenue when the Company has substantially completed its initial services under the franchise agreement, which typically occurs upon opening of the clinic.  The Company’s services under the franchise agreement include: training of franchisees and staff, site selection, construction/vendor management and ongoing operations support. The Company provides no financing to franchisees and offers no guarantees on their behalf.
 
Regional Developer Fees
. During
2011,
the Company established a regional developer program to engage independent contractors to assist in developing specified geographical regions. Under this program, regional developers pay a license fee ranging from
$7,250
to
25%
of the then current franchise fee, for each franchise they receive the right to develop within the region. Each regional developer agreement establishes a minimum number of franchises that the regional developer must develop. Regional developers receive fees ranging from
$14,500
to
$19,950
which are collected from franchisees upon the sale of franchises within their region and a royalty of
3%
of sales generated by franchised clinics in their region. Regional developer license fees paid to us are non-refundable and are recognized as revenue when the Company has performed substantially all initial services required by the regional developer agreement, which generally is considered to be upon the opening of each franchised clinic. Accordingly, revenue is recognized on a pro-rata basis determined by the number of franchised clinics to be opened in the area covered by the regional developer agreement. Upon the execution of a regional developer agreement, the Company estimates the number of franchised clinics to be opened, which is typically consistent with the contracted minimum. The Company reassesses the number of clinics expected to be opened as the regional developer performs under its regional developer agreement. When a material change to the original estimate becomes apparent, the amount of revenue to be recognized per clinic is revised on a prospective basis, and the unrecognized fees are allocated among, and recognized as revenue upon the opening of, the expected remaining unopened franchised clinics within the region. Certain regional developer agreements provide that no additional fee is required for franchises developed by the regional developer above the contracted minimum, while other regional developer agreements require a supplemental payment. The franchisor’s services under regional developer agreements include site selection, grand opening support for the clinics, sales support for identification of qualified franchisees, general operational support and marketing support to advertise for ownership opportunities. Several of the regional developer agreements grant the Company the option to repurchase the regional developer’s license. 
 
 
Revenues and Management Fees from Company Clinics.  
The Company earns revenues from clinics that it owns and operates or manages throughout the United States.  In those states where the Company owns and operates the clinic, revenues are recognized when services are performed. The Company offers a variety of membership and wellness packages which feature discounted pricing as compared with its single-visit pricing.  Amounts collected up front for membership and wellness packages are recorded as deferred revenue and recognized when the service is performed.  In other states where state law requires the chiropractic practice to be owned by a licensed chiropractor, the Company enters into a management agreement with the doctor’s PC.  Under the management agreement, the Company provides administrative and business management services to the doctor’s PC in return for a monthly management fee.  When the collectability of the full management fee is uncertain, the Company recognizes management fee revenue only to the extent of fees expected to be collected from the PCs.
 
Royalties.
The Company collects royalties, as stipulated in the franchise agreement, equal to
7%
of gross sales, and a marketing and advertising fee currently equal to
2%
of gross sales. Certain franchisees with franchise agreements acquired during the formation of the Company pay a monthly flat fee. Royalties are recognized as revenue when earned. Royalties are collected bi-monthly
two
working days after each sales period has ended.
 
IT Related Income and Software Fees.
  The Company collects a monthly computer software fee for use of its proprietary chiropractic software, computer support, and internet services support. These fees are recognized on a monthly basis as services are provided. IT related revenue represents a flat fee to purchase a clinic’s computer equipment, operating software, preinstalled chiropractic system software, key card scanner (patient identification card), credit card scanner and credit card receipt printer. These fees are recognized as revenue upon receipt of equipment by the franchisee.
 
Advertising Costs
 
Advertising costs are expensed as incurred. Advertising expenses for years ended
December
31,
2016
and
2015
were
$2,279,572
and
$1,525,687,
respectively.
 
Income Taxes
 
Deferred income taxes are recognized for differences between the basis of assets and liabilities for financial statement and income tax purposes. The differences relate principally to depreciation of property and equipment and treatment of revenue for franchise fees and regional developer fees collected. Deferred tax assets and liabilities represent the future tax consequence for those differences, which will either be taxable or deductible when the assets and liabilities are recovered or settled. Deferred taxes are also recognized for operating losses that are available to offset future taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.
 
The Company accounts for uncertainty in income taxes by recognizing the tax benefit or expense from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities, based on the technical merits of the position. The Company measures the tax benefits and expenses recognized in the condensed consolidated financial statements from such a position based on the largest benefit that has a greater than
50%
likelihood of being realized upon ultimate resolution.
 
Loss per Common Share
 
Basic loss per common share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per common share is computed by giving effect to all potentially dilutive common shares including preferred stock, restricted stock, and stock options.
 
    Year Ended
 December 31,
    2016   2015
         
Net loss   $
(15,173,872
)   $
(8,797,321
)
                 
Weighted average common shares outstanding - basic    
12,696,649
     
10,042,001
 
Effect of dilutive securities:                
Stock options    
-
     
-
 
Weighted average common shares outstanding - diluted    
12,696,649
     
10,042,001
 
                 
Basic and diluted loss per share   $
(1.20
)   $
(0.88
)
 
The following table summarizes the potential shares of common stock that were excluded from diluted net loss per share, because the effect of including these potential shares was anti-dilutive:
 
    Year Ended
 December 31,
    2016   2015
Unvested restricted stock    
92,415
     
339,288
 
Stock options    
953,075
     
477,459
 
Warrants    
90,000
     
90,000
 
 
Stock-Based Compensation
 
The Company accounts for share based payments by recognizing compensation expense based upon the estimated fair value of the awards on the date of grant. The Company determines the estimated grant-date fair value of restricted shares using quoted market prices and the grant-date fair value of stock options using the Black-Scholes option pricing model. In order to calculate the fair value of the options, certain assumptions are made regarding the components of the model, including the estimated fair value of underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to the valuation. The Company recognizes compensation costs ratably over the period of service using the straight-line method.
 
Use of Estimates
 
The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Items subject to significant estimates and assumptions include the allowance for doubtful accounts, share-based compensation arrangements, fair value of stock options, useful lives and realizability of long-lived assets, classification of deferred revenue and deferred franchise costs, uncertain tax positions, realizability of deferred tax assets, impairment of goodwill and intangible assets, and purchase price allocations.
  
Recent Accounting Pronouncements
 
In
May,
2014,
the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No.
2014
-
09,
Revenue from Contracts with Customers
”, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard becomes effective for us on
January
1,
2018.
The Company has completed a preliminary review of ASU
2014
-
09
and does not expect the adoption of ASU
2014
-
09
to have a material impact on its revenues and management fees from company clinics or franchise royalty revenues. The Company is currently evaluating the impact of the adoption of this standard on recognition of revenue from franchise agreements, advertising fund revenue, and regional developer fee revenue. The Company is still evaluating its transition approach and expects to reach a decision in the
first
half of fiscal
2017.
 
In
August,
2014,
the FASB issued ASU No.
2014
-
15,
Presentation of Financial Statements - Going Concern: Disclosures about an Entity’s Ability to Continue as a Going Concern
.” The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within
one
year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity’s ability to continue as a going concern. The new guidance is effective for annual periods ending after
December
15,
2016,
and interim periods thereafter. The Company adopted this new standard as of
December
31,
2016.
The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements.
 
In
April,
2015,
the FASB issued ASU No.
2015
-
03,
Interest - Imputation of Interest (Subtopic
835
-
30):
Simplifying the Presentation of Debt Issuance Costs
.”  The update requires debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability instead of being presented as an asset.  Debt disclosures will include the face amount of the debt liability and the effective interest rate.  The update requires retrospective application and represents a change in accounting principle.  The update is effective for fiscal years beginning after
December
 
15,
2015.
  ASU
2015
-
03
did not have a material impact on the Company’s consolidated financial statements.
 
In
September,
2015,
the FASB issued ASU No.
2015
-
16,
Business Combinations (Topic
805):
Simplifying the Accounting for Measurement-Period Adjustments
.” The update requires than an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined, including the cumulative effect of the change in provisional amount as if the accounting had been completed at the acquisition date. The adjustments related to previous reporting periods since the acquisition date must be disclosed by income statement line item either on the face of the income statement or in the notes. The Company adopted this ASU during the
third
quarter of
2015.
Accordingly, the Company applied the amendments in this update to the measurement period adjustments made during the year and disclosed the adjustments in Note
2.
 
In
November,
2015,
the FASB issued ASU No.
2015
-
17,
Income Taxes (Topic
470):
Balance Sheet Classification of Deferred Taxes
.” The update eliminates the requirement to separate deferred income tax assets and liabilities into current and noncurrent amounts within a classified balance sheet. Under ASU
2015
-
17,
the presentation of deferred income taxes is simplified, as all deferred income tax assets and liabilities are to be classified as noncurrent. The existing requirement that deferred income tax assets and liabilities of a tax-paying component of an entity be offset and presented as a single amount is not affected by ASU
2015
-
17.
The Company has adopted the guidance under ASU
2015
-
17
retrospectively and prior periods were retrospectively adjusted.
 
In
January,
2016,
the FASB issued ASU No.
2016
-
01,
Financial Instruments - Overall (Subtopic
825
-
10),
Recognition and Measurement of Financial Assets and Financial Liabilities
,” which addresses certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. ASU
2016
-
01
will be effective for fiscal years beginning after
December
15,
2017,
including interim periods within those fiscal years, and early adoption is not permitted. The Company is currently evaluating the effect of adoption of this standard, if any, on its consolidated financial position, results of operations or cash flows.
 
 
In
February,
2016,
the FASB issued ASU No.
2016
-
02,
Leases (Topic
842).”
The changes require that substantially all operating leases be recognized as assets and liabilities on our balance sheet, which is a significant departure from the current standard, which classifies operating leases as off balance sheet transactions and accounts for only the current year operating lease expense in the statement of operations. The right to use the leased property is to be capitalized as an asset and the expected lease payments over the life of the lease will be accounted for as a liability. The effective date is for fiscal years beginning after
December
15,
2018.
While we have not quantified the impact this proposed standard would have on our consolidated financial statements, if our current operating leases are instead recognized on the consolidated balance sheet, it will result in a significant increase in the liabilities reflected on our consolidated balance sheet and in the interest expense and depreciation and amortization expense reflected in our consolidated statements of operations, while reducing the amount of rent expense. This could potentially decrease our reported net income.
 
In
March,
2016,
the FASB issued ASU
2016
-
09,
Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting
” (“ASU
2016
-
09”),
which amends ASC Topic
718,
Compensation – Stock Compensation (“ASC
718”).
The standard is intended to simplify several areas of accounting for share-based compensation arrangements, including the accounting for income taxes, classification of excess tax benefits on the statement of cash flows, forfeitures, statutory tax withholding requirements, classification of awards as either equity or liabilities, and classification of employee taxes paid on the statement of cash flows when an employer withholds shares for tax-withholding purposes. ASU
2016
-
09
is effective for interim and annual reporting periods beginning
January
1,
2017.
Early adoption is permitted. The Company is currently evaluating the method of adoption and impact the update will have on its consolidated financial statements and related disclosures.
  
In
April,
2016,
the FASB issued ASU No.
2016
-
10,
Revenue from Contracts with Customers (Topic
606):
Identifying Performance Obligations and Licensing
”, to clarify the following
two
aspects of Topic
606:
1)
identifying performance obligations, and
2)
the licensing implementation guidance. The effective date and transition requirements for these amendments are the same as the effective date and transition requirements of ASU
2014
-
09.
The Company is currently evaluating the impact of this amendment on its consolidated financial statements.
 
In
May,
2016,
the FASB issued ASU No.
2016
-
12,
Revenue from Contracts with Customers (Topic
606):
Narrow-Scope Improvements and Practical Expedients
”, to clarify certain core recognition principles including collectability, sales tax presentation, noncash consideration, contract modifications and completed contracts at transition and disclosures no longer required if the full retrospective transition method is adopted. The effective date and transition requirements for these amendments are the same as the effective date and transition requirements of ASU
2014
-
09.
The Company is currently evaluating the impact of this amendment on its consolidated financial statements.
 
In
August,
2016,
the FASB issued ASU No.
2016
-
15,
“Statement of Cash Flows (Topic
230):
Classification of Certain Cash Receipts and Cash Payments”.
This update addresses how certain cash inflows and outflows are classified in the statement of cash flows to eliminate existing diversity in practice. This update is effective for annual and interim reporting periods beginning after
December
15,
2017.
Early adoption is permitted. The Company is currently evaluating the impact of this amendment on its consolidated financial statements.
 
In
November,
2016,
the FASB issued ASU No.
2016
-
18,
Statement of Cash Flows (Topic
230):
Restricted Cash”
(a consensus of the FASB Emerging Issues Task Force), to provide guidance on the presentation of restricted cash or restricted cash equivalents in the statement of cash flow. The amendments should be applied using a retrospective transition method, and are effective for fiscal years beginning after
December
15,
2017,
including interim periods within those fiscal years. The Company is currently evaluating the impact of these amendments on its consolidated financial statements.
 
In
January,
2017,
the FASB issued ASU No.
2017
-
01,
Business Combinations (Topic
805):
Clarifying the Definition of a Business”,
to clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The amendments should be applied prospectively, and are effective for fiscal years beginning after
December
15,
2017,
including interim periods within those fiscal years. The Company is currently evaluating the impact of these amendments on its consolidated financial statements.